News >

Expert Explains Evolving Role of Radiotherapy in NSCLC

Caroline Seymour
Published: Thursday, May 31, 2018

James Urbanic, MD

James Urbanic, MD
Incorporating radiotherapy into the treatment of patients with oligometastatic or metastatic non–small cell lung cancer (NSCLC) is standard practice, but its optimal placement in the paradigm is less clear with the advent of immunotherapy and other treatment advances, said James Urbanic, MD.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Urbanic, associate professor of Radiation Medicine and Applied Sciences, University of California, San Diego, discussed the evolving role of radiotherapy in patients with oligometastatic and metastatic NSCLC.

OncLive: Please provide an overview of your presentation.

Urbanic: I spoke about when we should use radiation treatment in metastatic NSCLC, particularly in the setting in which a patient might have 1 to 3 relatively small metastases. Historically, chemotherapy has had modest effectiveness. Initially, surgeons pioneered this idea of taking out a few small metastatic sites. As radiation treatment has gotten better over the past number of years, we have gotten better at picking off small areas of disease with very high-dose radiation treatments.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x